KALA
KALA BIO, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.51
−9.57%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | 3.9M |
| Cost of Revenue | 54.0K | — | 259.0K | 303.0K | 2.6M |
| Gross Profit | (54.0K) | — | (259.0K) | (303.0K) | 1.3M |
| Operating Expenses | |||||
| R&D Expense | 6.6M | 18.8M | 21.8M | 18.6M | 17.7M |
| SG&A Expense | 17.8M | 23.6M | 18.3M | 20.3M | 65.0M |
| General & Admin Expense | 17.8M | 23.6M | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (3.4M) | (3.2M) | — | — | — |
| Total Operating Expenses | 20.9M | 39.2M | 40.2M | 38.9M | 82.7M |
| Cost and Expenses | 21.0M | 39.2M | 40.4M | 39.2M | 85.2M |
| Operating Income (EBIT) | (21.0M) | (39.2M) | (40.4M) | (39.2M) | (81.4M) |
| Non-Operating | |||||
| Interest Income | 484.0K | 1.1M | 2.1M | 2.7M | 664.0K |
| Interest Expense | 1.1M | 3.3M | 5.8M | 5.8M | 7.3M |
| Net Interest Income | (620.0K) | (2.1M) | (3.7M) | (3.1M) | (6.6M) |
| Other Non-Op Income/Expense | 10.9M | 12.2M | 1.9M | (3.0M) | 36.5M |
| Non-Operating Income (excl Interest) | (12.0M) | (15.5M) | (7.7M) | (2.8M) | (43.8M) |
| EBT (Pre-Tax Income) | (10.1M) | (27.0M) | (38.5M) | (42.2M) | (44.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (10.1M) | (27.0M) | (38.5M) | (42.2M) | (44.8M) |
| Earnings from Cont. Ops | (10.1M) | (27.0M) | (38.5M) | (42.2M) | (44.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (10.1M) | (27.0M) | (38.5M) | (42.2M) | (44.8M) |
| Per Share | |||||
| Basic EPS | ($81.82) | ($165.50) | ($507.50) | ($867.50) | ($1,474.00) |
| Diluted EPS | ($81.82) | ($165.50) | ($507.50) | ($867.50) | ($1,474.00) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $127.98 |
| Shares | |||||
| Basic Shares Outstanding | 74159 | 162965 | 75920 | 48640 | 30412 |
| Diluted Shares Outstanding | 74159 | 162965 | 75920 | 48640 | 30412 |
| Profitability Metrics | |||||
| EBITDA | (8.8M) | (23.4M) | (32.5M) | (36.1M) | (36.7M) |
| D&A | 182.0K | 317.0K | 259.0K | 303.0K | 860.0K |
| EBIT | (9.0M) | (23.7M) | (32.7M) | (36.4M) | (37.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026